upgrade to Tier 1 to access blurred content, display up to 300 records, and unlimited CSV download
Data last updated 2024-04-28 04:05:40 -0500 US CDT
Insider Sentiment
| Company Name | Sector | Industry | Shares Outstanding(Mil) | 52-week High/Low | Period | Acq/Dsp Transaction Countb | Ids/Sec/Mkt Quantc | Acq/Dsp Shares Amountb | Acq/Dsp PctSOd |
|---|---|---|---|---|---|---|---|---|---|
| Novavax Inc. | Health Care | Biological Products (Diagnostic And Non Diagnostic) | 139.95 |
3.5
11.4
4.1
|
3-month |
0 / 0
|
|
0 / 0
|
0.0 / 0.0 |
| 6-month |
0 / 0
|
|
0 / 0
|
0.0 / 0.0 |
Data last updated 2024-04-27 07:55:23 -0500 US CDT
Major Shareholders
| Shareholder | Relation | Report Date | Holding Pct | Sharesa | Shares(Previous Report Date)a | Transactions (3 month)b | Transactions (6 month)b |
|---|---|---|---|---|---|---|---|
| Cadila Pharmaceuticals Ltd | 10% Owner | 2014-03-21 | 6.8% | 9500000 (NA%, NA%) | () | ||
| Modi Rajiv I. | Director | 2015-06-18 | 1.8% | 2500000 (-14.7%, NA%) | 2933053 (2015-06-15) | ||
| Boudreaux Gail | Director | 2016-09-21 | 0.1% | 200000 (100.0%, NA%) | 100000 (2015-06-19) | ||
| Hahn Timothy Jon | SVP, Manufacturing | 2015-02-03 | 0.1% | 110485 (9.2%, NA%) | 101156 (2014-10-03) | ||
| Young James F | Director | 2023-06-13 | 0.1% | 70090 (7.0%, NA%) | 65490 (2022-06-21) | ||
| Dubovsky Filip | President, R&D | 2024-03-12 | 0.0% | 66613 (4.4%, 23.9%) | 63834 (2024-03-11) | ||
| Wilson Russell P | SVP, Business Development | 2015-02-03 | 0.0% | 64939 (8.4%, NA%) | 59889 (2014-08-04) | ||
| Mott David M | Director | 2023-06-13 | 0.0% | 43800 (7.6%, NA%) | 40700 (2022-06-21) | ||
| Jacobs John C | President and CEO | 2024-01-25 | 0.0% | 43104 (NA%, NA%) | () | ||
| Phillips Barclay A | SVP, Chief Financial Officer | 2017-08-01 | 0.0% | 38669 (5.6%, NA%) | 36612 (2017-05-11) | ||
| Douglas Richard | Director | 2023-06-13 | 0.0% | 37250 (9.1%, NA%) | 34150 (2022-06-21) | ||
| Trizzino John | President and COO | 2024-03-12 | 0.0% | 27972 (9.3%, 162.5%) | 25590 (2024-03-11) | ||
| Kelly James Patrick | EVP, CFO and Treasurer | 2024-03-12 | 0.0% | 13285 (21.8%, 189.8%) | 10903 (2024-03-11) | ||
| Herrmann John A Iii | EVP, Chief Legal Officer | 2023-12-18 | 0.0% | 13233 (-12.9%, NA%) | 15217 (2023-06-27) | ||
| King Rachel K. | Director | 2023-06-13 | 0.0% | 12250 (33.9%, NA%) | 9150 (2022-06-21) | ||
| Rodgers Richard J | Director | 2023-10-31 | 0.0% | 3800 (NA%, NA%) | () |
a Total of direct and indirect accounts with percentage change comparing with (previous report, 3 months ago). The latter is NA when no change was found in the last 3 months.
Notice: Shares amount and percentage change 1) do not reflect intraday conversion and execution of derivative securities. 2) may subject to correction on amendment filing.
b Vital&Spontaneous transactions of the past 3 and 6 months, respectively. For acquisitions, code P (open market purchase), L (small acquisition), and I (at discretion of broker) are counted. For dispositions, code S (open market sell), D (sell back to issuer) and I (at discretion of broker) are counted. "C:" count of number of transactions. "S:" shares amount involved in corrresponding transactions. "P:" average per share price of the transactions (for reference only). Horizontal bar chart denotes shares amount of acquisitions and dispositions. Black thin bar is fixed size ruler for easy comparison between reporters.
c Quantile value of transaction count in b among industry peers, sector peers, and the market, respectively.
d Percentage of transaction shares amount to shares outstanding.
Notice: red exclamation mark (!) represents the reporter has Form 4 amendment filings in the latest three reports.
Non-derivative Transactions Chart
Tips: Click legend to show single series Click any bar to highlight corresponding transaction records
what is this?
Non-derivative Transactions Table
CSV download
Tips: Click legend to show single series Click any bar to highlight corresponding transaction records what is this?
|
|
|
Tips: type "code_p" to show transactions with code "P".
| Filing Date | Transaction Date | Operation Date | Original Filing | Reporter | Relation | Opr | Amounta | %(Owned)b | ‱(SO)c | Avg Prcd | Account | Type | Full Name | Code | Remain | Shares Outstanding (Million)e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-12 | 2024-03-10 | 2024-03-10 | 4 | Kelly James Patrick | EVP, CFO AND TREASURER | acq | 4608.0 | 29.71 | 0.33 | 0.0 | Direct | Common Stock | NOVAVAX INC | code M | 15511.0 | 139.95 (NVAX) |
| 2024-03-12 | 2024-03-10 | 2024-03-10 | 4 | Kelly James Patrick | EVP, CFO AND TREASURER | dsp | 2226.0 | 14.35 | 0.16 | 5.45 | Direct | Common Stock | NOVAVAX INC | code F | 13285.0 | 139.95 (NVAX) |
| 2024-03-12 | 2024-03-10 | 2024-03-10 | 4 | Dubovsky Filip | PRESIDENT, R&D | dsp | 2597.0 | 3.75 | 0.19 | 5.45 | Direct | Common Stock | NOVAVAX INC | code F | 66613.0 | 139.95 (NVAX) |
| 2024-03-12 | 2024-03-10 | 2024-03-10 | 4 | Dubovsky Filip | PRESIDENT, R&D | acq | 5376.0 | 7.77 | 0.38 | 0.0 | Direct | Common Stock | NOVAVAX INC | code M | 69210.0 | 139.95 (NVAX) |
| 2024-03-12 | 2024-03-10 | 2024-03-10 | 4 | Trizzino John | PRESIDENT AND COO | dsp | 2226.0 | 7.37 | 0.16 | 5.45 | Direct | Common Stock | NOVAVAX INC | code F | 27972.0 | 139.95 (NVAX) |
| 2024-03-12 | 2024-03-10 | 2024-03-10 | 4 | Trizzino John | PRESIDENT AND COO | acq | 4608.0 | 15.26 | 0.33 | 0.0 | Direct | Common Stock | NOVAVAX INC | code M | 30198.0 | 139.95 (NVAX) |
| 2024-03-11 | 2024-03-07 | 2024-03-07 | 4 | Trizzino John | EVP, CCO AND CBO | acq | 28890.0 | 73.06 | 2.06 | 0.0 | Direct | Common Stock | NOVAVAX INC | code M | 39545.0 | 139.95 (NVAX) |
| 2024-03-11 | 2024-03-07 | 2024-03-07 | 4 | Trizzino John | EVP, CCO AND CBO | dsp | 13955.0 | 35.29 | 1.0 | 5.61 | Direct | Common Stock | NOVAVAX INC | code F | 25590.0 | 139.95 (NVAX) |
| 2024-03-11 | 2024-03-07 | 2024-03-07 | 4 | Dubovsky Filip | PRESIDENT, R&D | acq | 19444.0 | 26.55 | 1.39 | 0.0 | Direct | Common Stock | NOVAVAX INC | code M | 73226.0 | 139.95 (NVAX) |
| 2024-03-11 | 2024-03-07 | 2024-03-07 | 4 | Dubovsky Filip | PRESIDENT, R&D | dsp | 9392.0 | 12.83 | 0.67 | 5.61 | Direct | Common Stock | NOVAVAX INC | code F | 63834.0 | 139.95 (NVAX) |
| 2024-03-11 | 2023-09-12 | 2024-03-07 | 4 | Kelly James Patrick | EVP, CFO AND TREASURER | acq | 12224.0 | 72.73 | 0.87 | 0.0 | Direct | Common Stock | NOVAVAX INC | code M | 16808.0 | 139.95 (NVAX) |
| 2024-03-11 | 2023-09-12 | 2024-03-07 | 4 | Kelly James Patrick | EVP, CFO AND TREASURER | dsp | 5905.0 | 35.13 | 0.42 | 5.61 | Direct | Common Stock | NOVAVAX INC | code F | 10903.0 | 139.95 (NVAX) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | O'hara Elaine | EVP, CHIEF STRATEGY OFFICER | acq | 19600.0 | 100.0 | 1.4 | 5.39 | Direct | Common Stock | NOVAVAX INC | code M | 19600.0 | 139.95 (NVAX) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | O'hara Elaine | EVP, CHIEF STRATEGY OFFICER | dsp | 5375.0 | 27.42 | 0.38 | 5.39 | Direct | Common Stock | NOVAVAX INC | code F | 14225.0 | 139.95 (NVAX) |
| 2024-01-25 | 2024-01-23 | 2024-01-23 | 4 | Jacobs John C | PRESIDENT AND CEO | dsp | 40093.0 | 48.19 | 3.38 | 4.26 | Direct | Common Stock | NOVAVAX INC | code F | 43104.0 | 118.79 (NVAX) |
| 2024-01-25 | 2024-01-23 | 2024-01-23 | 4 | Jacobs John C | PRESIDENT AND CEO | acq | 83197.0 | 100.0 | 7.0 | 0.0 | Direct | Common Stock | NOVAVAX INC | code M | 83197.0 | 118.79 (NVAX) |
| 2023-12-18 | 2023-12-14 | 2023-12-14 | 4 | Trizzino John | EVP, CCO AND CBO | dsp | 773.0 | 6.76 | 0.07 | 5.69 | Direct | Common Stock | NOVAVAX INC | code F | 10655.0 | 118.79 (NVAX) |
| 2023-12-18 | 2023-12-14 | 2023-12-14 | 4 | Trizzino John | EVP, CCO AND CBO | acq | 1600.0 | 14.0 | 0.13 | 0.0 | Direct | Common Stock | NOVAVAX INC | code M | 11428.0 | 118.79 (NVAX) |
| 2023-12-18 | 2023-12-14 | 2023-12-14 | 4 | Dubovsky Filip | PRESIDENT, R&D | acq | 2833.0 | 5.14 | 0.24 | 5.69 | Direct | Common Stock | NOVAVAX INC | code M | 55150.0 | 118.79 (NVAX) |
| 2023-12-18 | 2023-12-14 | 2023-12-14 | 4 | Dubovsky Filip | PRESIDENT, R&D | dsp | 1368.0 | 2.48 | 0.12 | 5.69 | Direct | Common Stock | NOVAVAX INC | code F | 53782.0 | 118.79 (NVAX) |
| 2023-12-18 | 2023-12-14 | 2023-12-14 | 4 | Herrmann John A Iii | EVP, CHIEF LEGAL OFFICER | dsp | 700.0 | 5.02 | 0.06 | 5.69 | Direct | Common Stock | NOVAVAX INC | code F | 13233.0 | 118.79 (NVAX) |
| 2023-12-18 | 2023-12-14 | 2023-12-14 | 4 | Herrmann John A Iii | EVP, CHIEF LEGAL OFFICER | acq | 2100.0 | 15.07 | 0.18 | 0.0 | Direct | Common Stock | NOVAVAX INC | code M | 13933.0 | 118.79 (NVAX) |
| 2023-11-07 | 2023-11-05 | 2023-11-05 | 4 | Dubovsky Filip | PRESIDENT, R&D | acq | 1400.0 | 2.64 | 0.15 | 7.06 | Direct | Common Stock | NOVAVAX INC | code M | 52994.0 | 94.4 (NVAX) |
| 2023-11-07 | 2023-11-05 | 2023-11-05 | 4 | Dubovsky Filip | PRESIDENT, R&D | dsp | 677.0 | 1.28 | 0.07 | 7.06 | Direct | Common Stock | NOVAVAX INC | code F | 52317.0 | 94.4 (NVAX) |
| 2023-10-31 | 2023-10-29 | 2023-10-29 | 4 | Rodgers Richard J | DIRECTOR | acq | 3800.0 | 100.0 | 0.4 | 0.0 | Direct | Common Stock | NOVAVAX INC | code M | 3800.0 | 94.4 (NVAX) |
Derivative Transactions Chart
Tips: Click legend to show single series Click any bar to highlight corresponding transaction records
what is this?
Derivative Transactions Table
Tips: Click legend to show single series Click any bar to highlight corresponding transaction records what is this?
|
|
Tips: type "code_m" to show transactions with code "M".
| Filing Date | Transaction Date | Operation Date | Original Filing | Reporter | Relation | Opr | Amounta | %(Owned)b | ‱(SO)c | Avg Prcd | Account | Type | Full Name | Code | Remain | Shares Outstanding (Million)e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-26 | 2024-03-01 | 2024-03-01 | 4 | Kelly James Patrick | EVP, CFO & TREASURER | acq | 176000.0 | 100.0 | 12.58 | 0.0 | Direct | Restricted Stock Units | NOVAVAX INC | code A | 176000.0 | 139.95 (NVAX) |
| 2024-03-26 | 2024-03-01 | 2024-03-01 | 4 | Casey Mark J | EVP, CLO & CORPORATE SECRETARY | acq | 12000.0 | 100.0 | 0.86 | 0.0 | Direct | Restricted Stock Units | NOVAVAX INC | code A | 12000.0 | 139.95 (NVAX) |
| 2024-03-26 | 2024-03-01 | 2024-03-01 | 4 | Trizzino John | EVP, CCO AND CBO | acq | 144000.0 | 100.0 | 10.29 | 0.0 | Direct | Restricted Stock Units | NOVAVAX INC | code A | 144000.0 | 139.95 (NVAX) |
| 2024-03-26 | 2024-03-01 | 2024-03-01 | 4 | O'hara Elaine | EVP, CHIEF STRATEGY OFFICER | acq | 120000.0 | 100.0 | 8.57 | 0.0 | Direct | Restricted Stock Units | NOVAVAX INC | code A | 120000.0 | 139.95 (NVAX) |
| 2024-03-26 | 2024-03-01 | 2024-03-01 | 4 | Dubovsky Filip | PRESIDENT, R&D | acq | 144000.0 | 100.0 | 10.29 | 0.0 | Direct | Restricted Stock Units | NOVAVAX INC | code A | 144000.0 | 139.95 (NVAX) |
| 2024-03-26 | 2024-03-01 | 2024-03-01 | 4 | Jacobs John C | PRESIDENT AND CEO | acq | 250000.0 | 100.0 | 17.86 | 0.0 | Direct | Restricted Stock Units | NOVAVAX INC | code A | 250000.0 | 139.95 (NVAX) |
| 2024-03-26 | 2024-03-01 | 2024-03-01 | 4 | Jacobs John C | PRESIDENT AND CEO | acq | 500000.0 | 100.0 | 35.73 | 5.39 | Direct | Stock Option (Right To Buy) | NOVAVAX INC | code A | 500000.0 | 139.95 (NVAX) |
| 2024-03-12 | 2024-03-10 | 2024-03-10 | 4 | Kelly James Patrick | EVP, CFO AND TREASURER | dsp | 4608.0 | 50.0 | 0.33 | 0.0 | Direct | Restricted Stock Units | NOVAVAX INC | code M | 4608.0 | 139.95 (NVAX) |
| 2024-03-12 | 2024-03-10 | 2024-03-10 | 4 | Dubovsky Filip | PRESIDENT, R&D | dsp | 5376.0 | 50.0 | 0.38 | 0.0 | Direct | Restricted Stock Units | NOVAVAX INC | code M | 5376.0 | 139.95 (NVAX) |
| 2024-03-12 | 2024-03-10 | 2024-03-10 | 4 | Trizzino John | PRESIDENT AND COO | dsp | 4608.0 | 50.0 | 0.33 | 0.0 | Direct | Restricted Stock Units | NOVAVAX INC | code M | 4608.0 | 139.95 (NVAX) |
| 2024-03-11 | 2024-03-07 | 2024-03-07 | 4 | Trizzino John | EVP, CCO AND CBO | dsp | 28890.0 | 100.0 | 2.06 | 0.0 | Direct | Restricted Stock Units | NOVAVAX INC | code M | 0.0 | 139.95 (NVAX) |
| 2024-03-11 | 2024-03-07 | 2024-03-07 | 4 | Dubovsky Filip | PRESIDENT, R&D | dsp | 19444.0 | 100.0 | 1.39 | 0.0 | Direct | Restricted Stock Units | NOVAVAX INC | code M | 0.0 | 139.95 (NVAX) |
| 2024-03-11 | 2023-09-12 | 2023-09-12 to 2024-03-07 | 4 | Kelly James Patrick | EVP, CFO AND TREASURER | dsp | 47224.0 | 65.89 | 3.37 | 0.0 | Direct | Restricted Stock Units | NOVAVAX INC | code A M | 24446.0
|
139.95 (NVAX) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | O'hara Elaine | EVP, CHIEF STRATEGY OFFICER | dsp | 19600.0 | 33.33 | 1.4 | 0.0 | Direct | Restricted Stock Units | NOVAVAX INC | code M | 39200.0 | 139.95 (NVAX) |
| 2024-01-25 | 2024-01-23 | 2024-01-23 | 4 | Jacobs John C | PRESIDENT AND CEO | dsp | 83197.0 | 33.33 | 7.0 | 0.0 | Direct | Restricted Stock Units | NOVAVAX INC | code M | 166393.0 | 118.79 (NVAX) |
| 2023-12-18 | 2023-12-14 | 2023-12-14 | 4 | Trizzino John | EVP, CCO AND CBO | dsp | 1600.0 | 100.0 | 0.13 | 0.0 | Direct | Restricted Stock Units | NOVAVAX INC | code M | 0.0 | 118.79 (NVAX) |
| 2023-12-18 | 2023-12-14 | 2023-12-14 | 4 | Dubovsky Filip | PRESIDENT, R&D | dsp | 2833.0 | 100.0 | 0.24 | 0.0 | Direct | Restricted Stock Units | NOVAVAX INC | code M | 0.0 | 118.79 (NVAX) |
| 2023-12-18 | 2023-12-14 | 2023-12-14 | 4 | Herrmann John A Iii | EVP, CHIEF LEGAL OFFICER | dsp | 2100.0 | 100.0 | 0.18 | 0.0 | Direct | Restricted Stock Units | NOVAVAX INC | code M | 0.0 | 118.79 (NVAX) |
| 2023-12-13 | 2023-12-11 | 2023-12-11 | 4 | Casey Mark J | EVP, CHIEF LEGAL OFFICER | acq | 125698.0 | 100.0 | 10.58 | 0.0 | Direct | Restricted Stock Units | NOVAVAX INC | code A | 125698.0 | 118.79 (NVAX) |
| 2023-12-13 | 2023-12-11 | 2023-12-11 | 4 | Casey Mark J | EVP, CHIEF LEGAL OFFICER | acq | 144694.0 | 100.0 | 12.18 | 5.57 | Direct | Stock Options (Right To Buy) | NOVAVAX INC | code A | 144694.0 | 118.79 (NVAX) |
| 2023-11-07 | 2023-11-05 | 2023-11-05 | 4 | Dubovsky Filip | PRESIDENT, R&D | dsp | 1400.0 | 100.0 | 0.15 | 0.0 | Direct | Restricted Stock Units | NOVAVAX INC | code M | 0.0 | 94.4 (NVAX) |
| 2023-10-31 | 2023-10-29 | 2023-10-29 | 4 | Rodgers Richard J | DIRECTOR | dsp | 3800.0 | 33.33 | 0.4 | 0.0 | Direct | Restricted Stock Units | NOVAVAX INC | code M | 7600.0 | 94.4 (NVAX) |
Form 3 CSV download
| Filing Date | Date requiring statement | Form Type | Reporter | Relation | Amounta | ‱(SO)c | Avg Excercisable Prcd | Account | Type | Full Name | Shares Outstanding (Million)e |
|---|
a Sum of same type of securities in the form
b Relative to reporter's shares owned before (disposition) or after (acquisition) operation
c Relative to issuer's shares outstanding (1/10000)
d Average price for securities of the same type. Check the original form for detailed prices of multiple transactions
e Documented shares outstanding closest to the transaction date
Note: Corporate may change mapped CIK when merge or spin-off happen. Please report error if the ticker you searched for does not have up-to-date insider trading information.
Show up to 30 records per table for current tier. (Access Guide)